Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (April 2022)
28 slides from Inoviq's investor presentation, Apr 6, 2022
Slide 1: Investor Presentation
Investor Presentation For personal use only ASX: IIQ | 6 April 22
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by INOVIQ Limited (“INOVIQ” or the “Company”) based on Actual results, performance or achievements could be significantly different from those expressed information available to it as at the date of this presentation. This presenta
Slide 3: Introduction
Introduction For personal use only There is a major unmet need for non-invasive, accurate and reliable diagnostic tests for earlier detection of cancer and other diseases. INOVIQ’s technologies enable earlier and more accurate detection - improving treatment options, patient outcomes & survival. 3 |
Slide 4: Company Overview
Company Overview For personal use only INOVIQ Ltd Financial information (ASX:IIQ) • Developing diagnostic and exosome-based solutions for cancer and Ordinary shares 92,018,702 other diseases Share price (1/4/22) A$0.880 • Proprietary technology platforms for biomarker isolation and Market capitalisa
Slide 5: Where we Sit in the Diagnostic Continuum
Where we Sit in the Diagnostic Continuum For personal use only BEFORE DIAGNOSIS AFTER DIAGNOSIS PREDICTION SCREENING DIAGNOSIS PROGNOSIS MONITORING Genetic tests to predict Tests for early detection Tests for confirming a Tests for staging and Tests for monitoring the risk of developing a of cancer
Slide 6: Global Cancer Diagnostics Market
Global Cancer Diagnostics Market For personal use only Important unmet needs Cancers are often diagnosed at late-stage 4.9m prevalence Prevalence 7.8m after symptoms have appeared, resulting 1.1m incidence $3.3b $4.2b Incidence 2.3m in poor prognosis. PROSTATE BREAST CANCER CANCER 375k deaths Deaths
Slide 7: Our Technology Platforms
Our Technology Platforms For personal use only INOVIQ has patented technologies and products in-market SubB2M NETs BARD1 HTERT Highly specific probe that detects the Biomarker capture technology for Biomarker technology covering various Immunocytochemistry (ICC) application pan-cancer marker Neu5Gc
Slide 8: Products and Pipeline
Products and Pipeline For personal use only ASSAY CLINICAL PRODUCT INDICATION PLATFORM USE RESEARCH DEVELOPMENT DEVELOPMENT REGISTRATION hTERT1 Bladder Cancer ICC Adjunct to cytology In-market EXO-NET-RUO Exosome Capture Device Research tool In-market SubB2M-BCM Breast Cancer Immunoassay Monitor
Slide 9: SubB2M | Neu5Gc Specific Probe
SubB2M | Neu5Gc Specific Probe For personal use only SubB2M: Improves specificity for cancer monitoring and detection • SubB2M detects a pan-cancer biomarker Neu5Gc found at elevated levels in multiple human cancers1 • INOVIQ holds the exclusive worldwide licence to SubB2M technology for diagnostic
Slide 10: SubB2M | Breast Cancer Performance
SubB2M | Breast Cancer Performance OVERALL SUBB2M SPR TEST PERFORMANCE For personal use only • POC data shows the SubB2M-based SPR test detected Breast Cancer at >95% sensitivity and 99% 100% SENSITIVITY SPECIFICITY 100% specificity across all stages (n = 118) 1,2,3 • Griffith conducted further work
Slide 11: SubB2M | Ovarian Cancer Performance
SubB2M | Ovarian Cancer Performance OVERALL SUBB2M SPR TEST PERFORMANCE For personal use only • POC data shows the SubB2M-based SPR test detected Ovarian Cancer at 100% sensitivity and 100% 100% 100% specificity across all stages (n = 69) 1,2 SENSITIVITY SPECIFICITY • Griffith conducted further work
Slide 12: SubB2M | Development Pathway
SubB2M | Development Pathway • SubB2M tests ready for transfer to ResearchDx, a contract diagnostics organization (CDO), for completion of feasibility and commercial assay development1 For personal use only • Assay classification and monitoring performance will be confirmed in retrospective clinical
Slide 13: NETs | Exosomes Explained
NETs I Exosomes Explained For personal use only Exosomal biomarkers Cells can communicate with each other by packaging messages (DNAs, RNAs, proteins & lipids) into nanovesicles (exosomes) and releasing them into biofluids (blood, saliva, urine). We can isolate exosomes from biofluids and read their
Slide 14: NETs | How our EXO-NET Technology Works
NETs I How our EXO-NET® Technology Works For personal use only Making exosome isolation commercially viable Exosomal mRNAs Exosomal Proteins Our NETs technology enables fast and efficient capture of cells, exosomes or biomolecules (e.g., proteins, DNA, RNA) from biofluids. EXO-NET® is our first prod
Slide 15: NETs | EXO-NET pan-exosome capture product
NETs I EXO-NET pan-exosome capture product For personal use only Our EXO-NET (RUO) product for exosome capture • EXO-NET pan-exosome capture tool is a ‘research use only’ (RUO) product for the isolation of exosomes from body fluids including plasma, urine and saliva • Meets an unmet need for the rap
Slide 16: NETs | Exosome-based diagnostics pipeline
NETs I Exosome-based diagnostics pipeline Collaboration with UQ1 to develop world-first For personal use only exosome-based ovarian cancer screening test1 “We are extremely pleased to collaborate with • UQ to develop exosome-based blood test for the earlier Australian-based company INOVIQ to combine
Slide 17: BARD1 | Technology and Autoantibody Tests
BARD1 | Technology and Autoantibody Tests For personal use only • BARD1 splice variants are produced by cancer cells n and formation, progression and poor prognosis Product Study (cancer:normal) AUC Sensitivity Specificity • BARD1 autoantibody (AAb) tests measure autoantibodies to BARD1 BARD1 OC-CA1
Slide 18: hTERT | ICC Test for Detection of hTERT
hTERT | ICC Test for Detection of hTERT For personal use only Anti-hTERT Antibody • hTERT test is an immunocytochemistry (ICC) assay that detects hTERT • Adjunct to urine cytology to assist bladder cancer diagnosis • Registered in US (FDA Class I), Europe (CE-IVD mark), South Korea (MFDS Class II) &
Slide 19: INOVIQ's Scalable Commercialisation Strategy
INOVIQ’s Scalable Commercialisation Strategy For personal use only 2 A well trodden path Commercialise as EARLY REVENUES & INITIAL Lab Developed Test INOVIQ has proven it can take a test from MARKET ACCEPTANCE (LDT) concept to commercialisation. Our strategy for commercializing diagnostics assets is
Slide 20: Strategy & Growth Plans
Strategy & Growth Plans For personal use only 20 | APRIL 2022
Slide 21: Achievements and Catalysts
Achievements and Catalysts For personal use only 1Q 2022 2Q 2022 3Q 2022 4Q 2022 2023 ✓ EXO-NET ✓ Commence SubB2M - EXO-NET ✓ Secure LDT laboratory - SubB2M BC test results collaborations (AU) assay development collaborations (ROW) partner - SubB2M OC test results & validation (CRO) ₋ SubB2M feasibi
Slide 22: Reasons to Invest
8 Reasons to Invest For personal use only Innovative Patented Strong Compelling Company Technology Pipeline Results Focused on diagnostic and Proprietary biomarker Multi-product pipeline Early data for SubB2M and 1 2 3 4 exosome-based solutions to isolation & detection for detection of common exosom
Slide 23: Contacts
Contacts For personal use only INOVIQ Ltd 23 Normanby Road Dr Leearne Hinch Notting Hill VIC 3168 Chief Executive Officer Australia e. lhinch@inoviq.com m. +61 400 414 416 p. +61 3 9548 7586 e. info@inoviq.com w. www.inoviq.com 23 | APRIL 2022
Slide 24: Appendices
Appendices For personal use only 24 | APRIL 2022
Slide 25: Strong Patent Portfolio
Strong Patent Portfolio For personal use only • Broad patent portfolio Patent Family Title Granted Pending Expiry protecting IIQ’s core SubB2M biomarker isolation and AU, BR, CA, PCT/AU2017/051230 (WO 2018/085888) Subtilase cytotoxin B subunit mutant CN, EP, IN, 2037 detection technologies, JP, KR,
Slide 26: Healthcare Experienced Board
Healthcare Experienced Board For personal use only DR GEOFF CUMMING PhD MAX JOHNSTON PHILIP POWELL Prof ALLAN CRIPPS AO PhD Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Healthcare and biotechnology director with Healthcare industry director and internat
Slide 27: Management
Management For personal use only DR LEEARNE HINCH DR GREG RICE PhD Dr ROCCO IANNELLO TONY DI PIETRO Chief Executive Officer Chief Scientific Officer Business Development and Licensing Director CFO & Company Secretary Dr Leearne Hinch BSc BVMS MBA is an Dr Greg Rice BSc PhD MHA GradDipMgt is an Dr Ro
Slide 28: Management
Management For personal use only DR EMILY STEIN PhD DR WAYNE JENSEN PhD SUSAN BELZER Technology Director (NETs) R&D Director Commercial Development Director Dr Emily Stein PhD is an experienced life Dr Wayne Jensen PhD is an experienced medtech Susan Belzer BSc MBA is an experienced clinical science